Independent effects of white matter hyperintensities on cognitive, neuropsychiatric, and functional decline: a longitudinal investigation using the National Alzheimer’s Coordinating Center Uniform Data Set

Christian Puzo1†, Caroline Labriola1†, Michael A. Sugarman1, Yorghos Tripodis1,2, Brett Martin1,3, Joseph N. Palmisano1,3, Eric G. Steinberg1, Thor D. Stein1,5,6, Neil W. Kowall1,4,5,6, Ann C. McKee1,4,5,6, Jesse Mez1,4, Ronald J. Killiany1,7,8, Robert A. Stern1,4,9† and Michael L. Alosco1,4†

Abstract

Background: Longitudinal investigations are needed to improve understanding of the contributions of cerebral small vessel disease to the clinical manifestation of Alzheimer’s disease, particularly in the early disease stages. This study leveraged the National Alzheimer’s Coordinating Center Uniform Data Set to longitudinally examine the association between white matter hyperintensities and neuropsychological, neuropsychiatric, and functional decline among participants with normal cognition.

Methods: The sample included 465 participants from the National Alzheimer’s Coordinating Center Uniform Data Set who had quantitated volume of white matter hyperintensities from fluid-attenuated inversion recovery MRI, had normal cognition at the time of their MRI, and were administered the National Alzheimer’s Coordinating Center Uniform Data Set neuropsychological test battery within 1 year of study evaluation and had at least two post-MRI time points of clinical data. Neuropsychiatric status was assessed by the Geriatric Depression Scale-15 and Neuropsychiatric Inventory-Questionnaire. Clinical Dementia Rating Sum of Boxes defined functional status. For participants subsequently diagnosed with mild cognitive impairment (MCI) or dementia, their impairment must have been attributed to Alzheimer’s disease (AD) to evaluate the relationships between WMH and the clinical presentation of AD.

(Continued on next page)
**Introduction**

Advances in the development of in vivo biomarkers of beta-amyloid (Aβ), tau, and neurodegeneration have increased the ability to accurately detect Alzheimer’s disease (AD) neuropathologic changes, even before onset of clinical symptoms [1–9]. In vivo biomarkers of specific (e.g., Aβ neuritic plaques) and non-specific (e.g., hippocampal atrophy) pathologies further assist with the study of disease mechanisms, monitoring of disease progression, and response to therapeutics. A popular target of clinical research into the pathogenesis of AD has been T2 fluid-attenuated inversion recovery (FLAIR) magnetic resonance imaging (MRI) white matter hyperintensities (WMH). WMH are non-specific biomarkers of WM pathology (e.g., gliosis, demyelination, axonal loss), but are often interpreted to reflect cerebral small vessel disease (CSVD) associated with aging and cardiovascular disease (CVD) [10–19]. CSVD is similarly a broad term that refers to pathologies that affect the cerebral arteries, arterioles, capillaries, and venules [20]. WMH are indeed often used to study the role of CSVD in the clinical and pathological manifestation of AD [10, 18, 21–31].

WMH may be evident on MRI long before symptom onset in patients with AD and may uniquely contribute to the clinical presentation of the disease. Lee et al. showed that participants who were autosomal-dominant for AD had increased burden of WMH 6 years prior to expected clinical onset of symptoms and that WMH were associated with Aβ levels in the cerebrospinal fluid (CSF) among carriers only [23]. Another study also reported WMH to demonstrate stronger associations with AD-specific pathology (e.g., Aβ) compared to traditional AD neuroimaging biomarkers (e.g., floroudeoxyglucose [FDG]-PET, hippocampal volume) and cognitive test performance in cognitively normal controls from the AD Neuroimaging Initiative (ADNI) [21]. WMH commonly correlate with frontal lobe dysfunction [32–37] and CSVD is classically associated with impaired frontal-mediated cognitive systems [37–42]. CSVD and other white matter pathologies might contribute to the 10–40% of patients who have underlying AD pathology and present with an initial behavioral and/or dysexecutive syndrome [1, 43–45] and not a traditional amnestic profile.

Longitudinal studies are necessary to elucidate the role of WMH in the clinical manifestation of AD. There have been equivocal reports on the ability of WMH to predict diagnostic conversion. Several studies have shown that WMH predict diagnostic conversion across the AD clinical continuum [46–51]. In contrast, other studies have failed to observe WMH as a significant predictor of diagnostic conversion, particularly from mild cognitive impairment (MCI) to dementia [52–54]. Some of these inconsistencies may be related to differences in the measurement of WMH (e.g., quartiles versus continuous) [50], examination of baseline WMH compared to change in WMH over time [50], and/or the pathological heterogeneity of clinical AD [55]. Alternatively, if WMH are an early indicator of cognitive decline, they may be more sensitive to the subtle variations in neuropsychological test performance over time [41, 42, 56–58], specifically frontal systems functioning [35, 41, 42, 58], as opposed to diagnostic conversion.

Although WMH contribute to clinical heterogeneity in AD [35, 41, 42, 58], their effects in the early stages of disease (e.g., preclinical) are not well understood. Here, we leveraged the National Alzheimer’s Coordinating Center (NACC) Uniform Data Set (UDS) to conduct a longitudinal examination on the independent effects of FLAIR MRI WMH on neuropsychological, neuropsychiatric, and functional decline in participants who had normal cognition (NC) at baseline. These associations were examined after accounting for traditional risk factors and...
MRI biomarkers for AD, such as APOE ε4 carrier status, total brain volume (TBV), and hippocampal volume. We hypothesized that greater baseline volume of WMH would be associated with an accelerated cognitive, neuropsychiatric, and functional decline.

Methods
Participants and design
The sample included 465 participants from the NACC-UDS (see Fig. 1). The NACC was established in 1999 by the National Institute on Aging (NIA) to promote AD research by providing a publicly available database of clinical data gathered from NIA-funded Alzheimer’s Disease Centers (ADCs) across the USA. Since 2005, ADCs have contributed standardized cognitive, behavioral, and functional participant data from approximately annual study visits to a common database, known as the NACC-UDS [59–62]. A subset of ADCs also voluntarily submit structural MRI data [63] to NACC to include with the UDS. All ADCs that contribute data to NACC are approved by their local Institutional Review Board and participants provided informed consent at the ADC where they completed their study visits.

For this study, a formal data request was submitted to NACC to obtain UDS data for participants who were determined to have NC at their initial study visit, completed at least two follow-up visits, and had quantitated MRI data available, including total volume of T2 FLAIR WMH, at any time. The set includes data from the June 2018 NACC data freeze. The initial data set included 569 participants and the sample size was reduced to 465 after the following restrictions were applied: (1) the MRI must have been completed within 1 year of a NACC-UDS study visit and this was designated as the “baseline visit” for the purposes of this study (note that this did not necessarily correspond to the first overall NACC-UDS visit), (2) the participant must have been determined to have NC at the baseline MRI study visit, (3) participants must have had at least two follow-up visits following the baseline MRI visit, and (4) for participants subsequently diagnosed with MCI or dementia, their impairment must have been attributed to possible or probable AD to evaluate the relationships between WMH and the clinical presentation of AD. The final analytic sample of 465 participants included those who remained stable with NC from baseline, in addition to those who converted to MCI due to AD or AD dementia. There were 52 participants excluded for non-AD etiologies (n = 28 vascular disease, n = 3 Lewy body disease, n = 2 traumatic brain injury, n = 1 neoplasm, n = 1 normal pressure hydrocephalus, n = 3 depression, n = 3 other psychiatric disease, n = 4 medical illness, n = 1 medication effects, n = 6 other/unknown). Individuals with cognitive impairment due to non-AD causes were evaluated in a sensitivity analysis.

Fig. 1 Participant flow chart. Abbreviations: AD = Alzheimer’s disease; CSF = cerebrospinal fluid; MRI = magnetic resonance imaging; NACC = National Alzheimer’s Coordinating Center
Measures

Volumetric MRI

Volumetric MRI quantitation for NACC was conducted by the Imaging of Dementia & Aging (IDEA) Lab at the University of California Davis (Director: Charles DeCarli, M.D.; http://idealab.ucdavis.edu/). Total volume of WMH (in cm$^3$) was calculated using T2 FLAIR scan files. Methods for WMH estimation were similar to those used for the ADNI-II [64]; a full description of methods can be found at https://www.alz.washington.edu/WEB/adni_proto.pdf and are described by Alosco et al. [63]. The TBV composite was calculated as the sum of total gray and white matter segmentations. Total hippocampal volume (a summary composite of the right and left hemispheres) was also calculated. TBV and hippocampal volume were included as covariates due to their sensitivity to clinical and pathological AD [50, 65].

Neuropsychological and neuropsychiatric functioning

All participants were administered a standardized battery of common neuropsychological tests at each study visit. These NACC-UDS tests are described elsewhere [59, 61, 62, 66]. Due to a recent change in the UDS neuropsychological test battery [62], the tests that have been most consistently administered over time were examined to maximize longitudinal data analyses. This resulted in 429 participants with UDS v.2.0 at baseline, with the remaining participants having had UDS v.1.0. Specific tests examined included the Mini-Mental State Examination (MMSE), Short Form of the Boston Naming Test (BNT), Animal Fluency and Vegetable Fluency (raw scores combined into one “Semantic Fluency” score), Trail Making Test (TMT) Parts A and B, Wechsler Adult Intelligence Scale-Revised Digit Symbol Coding (WAIS-R DSC), and Logical Memory Immediate (LM-IA) and Delayed Recall (LM-IIA). Lower scores reflect worse performance for all tests, with the exception of TMT A and B where lower scores are better.

Neuropsychiatric functioning was assessed at each study visit using the 15-item Geriatric Depression Scale (GDS-15) and the Neuropsychiatric Inventory-Questionnaire (NPI-Q). The GDS-15 is a self-report measure of 15 yes/no questions pertaining to the presence of depression symptoms. Scores range from 0 to 15 and higher scores represent greater depressive symptoms. The NPI-Q asks study partners to evaluate the presence or absence of 12 neuropsychiatric symptoms over the past month. Each symptom is rated on a scale from 0 (absent) to 3 (severe). Symptoms were separated into four domains based on the result of a factor analysis from a sample of outpatients with dementia [67]: hyperactivity (agitation, euphoria, irritability, disinhibition, aberrant motor behavior), psychotic symptoms (delusions, hallucinations), mood (depression, apathy, nighttime behavior disturbances, appetite/eating abnormalities), and anxiety (single anxiety item).

Clinical diagnoses and dementia severity

Clinical research diagnoses of cognitive status (i.e., NC; cognitively impaired, not MCI; MCI; dementia) were made at each UDS visit using established criteria for MCI [68, 69] and AD dementia [70, 71]. For versions 1 and 2 of the UDS, MCI due to AD and AD dementia diagnoses were based on the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and the Alzheimer’s Disease and Related Disorders Association (ADRDA) diagnostic criteria [71]. The Clinical Diagnosis Form D1 was updated in version 3 of the UDS [62] to adopt the 2011 National Institute on Aging-Alzheimer’s Association (NIA-AA) criteria for MCI due to AD [69] and AD dementia [70]. For the current sample, baseline clinical AD diagnoses were based on the UDS versions 1 and 2 NINCDS/ADRSA criteria (although all participants in this sample were cognitively normal at baseline). A subset of the follow-up clinical AD diagnoses were also made using the updated NIA-AA criteria. The NACC created a derived variable (i.e., NACCALZD) to harmonize UDS versions 1–3, and this variable was used to determine AD as the suspected etiology for those who converted at follow-up UDS visits. All diagnoses were based on available UDS data, including neuropsychological, neurological, and neuropsychiatric test results, and, when available, neuroimaging. Sum of Boxes from the CDR® Dementia Staging Instrument assessed the overall severity of clinical impairment [72, 73].

Demographic, medical, and genotype characteristics

Demographic and medical characteristics were ascertained during approximately annual UDS clinical evaluations. Blood samples are collected by the individual ADCs to determine APOE ε4 allele status, which was dichotomized into ε4 carriers versus non-carriers for the current analyses.

Statistical analyses

Study hypotheses were tested using generalized linear models (GLM) estimated by generalized estimating equations (GEE) and binomial logistic regression models. Multiple linear regression models estimated by GEE were conducted using the “geepack” package [74] for R [75]. GEE using an autoregressive (AR1) correlation structure tested whether baseline volume of WMH predicted the slope of change over time of the following outcomes: (1) neuropsychological test scores: MMSE, Semantic Fluency, TMT-A and B, LM-IA and LM-IIA, BNT, and WAIS-R DSC, (2) CDR Sum of Boxes, and (3) GDS-15 and NPI-Q scores. All outcome raw scores were
transformed into z-scores based on the performance of the sample at baseline in order to facilitate effect size comparisons between the variables of interest. All study visits were included in the GEE models. Binomial logistic regression models tested whether baseline total volume of WMH predicted conversion from NC to MCI due to AD at any time point; an insufficient number of participants progressed from NC to AD dementia to warrant reliable analyses. All models included all participants (N = 465).

For all models, the WMH variable was log-transformed due to a positively skewed distribution. Age at the time of the MRI scan, sex, race (White versus other), years of education, APOE e4 carrier status, TBV, and hippocampal volume were included as covariates in all GEE and logistic regression models. The baseline score on the relevant outcome variable of interest was included in all models. The main predictor variable of interest was the interaction between volume of WMH and the amount of time (in years) elapsed since the baseline MRI. Time since baseline in the models was included to facilitate examination of WMH and the slope of these variables over time, as well as account for differences in follow-up length and potential learning effects on the neuropsychological tests. Previous research has used total number of visits to test for learning effects in the UDS battery [66, 76]. Time since baseline is highly correlated with the number of UDS visits (r = 0.97); therefore, it was used to account for the total number of times an individual was exposed to the neuropsychological tests. Total number of visits was not also included due to violation of multicollinearity assumptions because of its correlation with time since baseline. The interpretation of the coefficients is based on SD unit increases between WMH and the corresponding outcome. p values for WMH effects from the GEE models were false discovery rate (FDR)-adjusted to the number of outcomes compared.

A series of sensitivity analyses were conducted. Because symptoms of depression are associated with WMH [77] and neuropsychological test performance [78], analyses were repeated with GDS-15 scores as a covariate to determine potential confounding from depression symptom severity. Analyses were also repeated with CVD risk factors associated with CVD (i.e., systolic blood pressure, and diagnostic history of hypertension, diabetes, and hypercholesterolemia) as covariates to determine their potential confounding. Lastly, all analyses were repeated with intracranial volume entered as a covariate instead of TBV.

Results
Participant demographics are shown in Table 1. All participants had a diagnosis of NC at the baseline MRI visit and were followed for an average of 5 years. A total of 56 participants (12.0%) had a diagnosis of MCI due to AD or AD dementia at any subsequent study visit; 51 participants converted from NC to MCI due to AD and 5 participants progressed directly from NC to AD dementia at consecutive study visits. Of the individuals who converted to MCI due to AD, 92.2% (47 of 51) had a diagnosis of amnestic MCI. There were eight participants who reverted from MCI to NC. Results for diagnostic conversion as an outcome remained unchanged without these participants included and therefore these participants were not excluded.

Neuropsychological, neuropsychiatric, and functional decline
Table 2 displays the results of GLM estimated by GEE. Only the results for the interaction between WMH and time since baseline are shown to demonstrate the role of WMH in predicting the slope of subsequent change. Higher baseline WMH were associated with decline on the following neuropsychological tests, in rank order of

Table 1 Sample demographic and clinical characteristics. The total sample included 465 participants from the National Alzheimer’s Coordinating Uniform Data Set. All participants were diagnosed with normal cognition at the baseline study visit. The final analytic sample included those who remained stable with normal cognition and those who converted to MCI due to AD or AD dementia (n = 56). APOE data were missing for six participants.

| Variable | Mean (SD) or n (%) | Range |
|----------|-------------------|-------|
| Age at baseline MRI visit | 68.9 (11.8) | 45–100 |
| Total length of follow-up (years) | 5.10 (2.14) | 1.45–11.67 |
| Total number of follow-up visits | 4.62 (1.91) | 2–10 |
| Sex | 146 (31.4%) male | |
| Years of education | 15.37 (3.41) | 1–25 |
| Ethnicity | 86.9% white, 10.3% AA, 2.8% other | |
| APOE e4 carrier status | 162 (35.3%) carriers | |
| Systolic blood pressure | 132 (18.8) | 78–198 |
| History of hypertension | 200 (43.0%) | |
| History of diabetes | 80 (17.2%) | |
| History of hypercholesterolemia | 224 (48.2%) | |
| WMH volume at baseline (cm³) | 4.70 (8.71) | 0–61.24 |
| Natural log of WMH at baseline | 0.45 (1.52) | –2.30–4.12 |
| Diagnosis at final study visit | | |
| Normal cognition | 417 (89.7%) | |
| MCI | 22 (4.7%) | |
| Dementia | 26 (5.6%) | |
| CDR Sum of Boxes at final study visit | 0.55 (1.83) | 0–18 |

Abbreviations: Aβ beta-amyloid, CDR Clinical Dementia Rating scale, MCI mild cognitive impairment, MRI magnetic resonance imaging, WMH white matter hyperintensities
Neuropsychiatric symptoms
Neuropsychological tests
TMT-B
NPI-Q
State Examination,
LM-IIA
Immediate Recall,
DSC (beta = 0.04) and WAIS-R DSC (beta = −0.04), LM-IA (beta = −0.04), TMT-A (beta = 0.03), and Semantic Fluency (beta = −0.03); there was a non-significant trend for LM-IIA (beta = −0.03, p = 0.05). There were no statistically significant effects for the MMSE or the BNT. For TMT-B and WAIS-R DSC, every one SD unit increase in baseline volume of WMH corresponded to a 0.04-unit SD decline in test performance per year. Figure 2 provides graphical representations of notable findings based on baseline WMH quartiles. For TMT-B, individuals in the highest two quartiles (i.e., greatest WMH burden) experienced a mean increase of 2.9 s per year, whereas individuals in the lowest quartile only slowed by 0.9 s per year. On the WAIS-R DSC, the highest quartile had a mean decline of 0.58, whereas the lowest quartile experienced a mean score increase of 0.11 per year. The mean slope for decline in Semantic Fluency was twice as steep among participants in the highest WMH quartile compared to the lowest WMH quartile (mean raw score decline of 0.61 words compared to 0.30 per year, respectively). Note that scores on the Logical Memory Immediate and Delayed Recall improved over time across all quartiles (likely due to the commonly observed practice effects [76]), but the rate of improvement was less for participants in the higher WMH quartiles.

Higher baseline volume of WMH corresponded to increases on the GDS-15 over time (p = 0.01). There were no significant effects for the NPI-Q sub-scores (ps > 0.10). Greater volume of WMH at baseline predicted increased scores on the CDR Sum of Boxes over time (p < 0.01). The participants in the lowest WMH quartile had a net slope of zero over time, whereas participants in the highest two quartiles had a mean raw score increase of 0.11 per year. However, after accounting for demographics, APOE ε4 carrier status, and length of follow-up for each participant, WMH were not a significant predictor of diagnostic change to MCI due to AD/AD dementia (p = 0.86). Similar null effects were observed when WMH quartiles were entered into the model rather than as a continuous variable.

The 52 individuals who were excluded from initial analyses due to non-AD impairment (for those who converted) were significantly older at baseline (mean age 75.5 years, p < 0.001). In sensitivity analyses that included individuals with impairment due to any etiology (i.e., AD as well as the 52 participants with other suspected pathologies), level of statistical significance remained across all neuropsychological, neuropsychiatric, and functional outcomes; in addition, the above trend for LM-IIA became statistically significant (p = 0.02). WMH were still not a significant predictor of conversion to amnestic MCI (n = 58) or non-amnestic MCI (n = 26).

**Table 2** Summary of results from the generalized linear models estimated by generalized estimating equations (GEE). Only the results for the interaction effect for WMH and the time since baseline are displayed as a demonstration of the role of WMH in predicting the slope of these variables over time. The interpretation of the standardized beta coefficients is based on SD unit increases between log-transformed WMH and corresponding outcomes. All outcomes were raw scores that were transformed into z-scores based on the performance of the sample at baseline in order to facilitate effect size comparisons between the variables of interest. For example, for the MMSE, for every one SD unit increase in WMH, MMSE raw scores declined by 0.16 SD units per year. Age at baseline, race, sex, years of education, APOE ε4 carrier status, baseline hippocampal volume, baseline total brain volume, and the baseline score on the variable of interest were included as covariates in all models. All p values are FDR-adjusted.

| Variable                | B     | SE   | p value |
|-------------------------|-------|------|---------|
| Clinical status         |       |      |         |
| CDR Sum of Boxes        | 0.126 | 0.035| < 0.01  |
| Neuropsychological tests|       |      |         |
| MMSE                    | −0.016| 0.016| 0.38    |
| Semantic Fluency        | −0.031| 0.007| < 0.01  |
| TMT-A                   | 0.031 | 0.007| < 0.01  |
| TMT-B                   | 0.040 | 0.007| < 0.01  |
| LM-IA                   | −0.040| 0.015| 0.02    |
| LM-IIA                  | −0.034| 0.015| 0.05    |
| BNT                     | −0.002| 0.014| 0.91    |
| WAIS-R DSC              | −0.040| 0.009| < 0.01  |
| Neuropsychiatric symptoms|      |      |         |
| GDS-15                  | 0.040 | 0.014| 0.01    |
| NPI-Q Hyperactivity     | 0.022 | 0.015| 0.23    |
| NPI-Q Mood              | 0.014 | 0.011| 0.27    |
| NPI-Q Psychosis         | 0.025 | 0.016| 0.19    |
| NPI-Q Anxiety           | 0.007 | 0.014| 0.66    |

**Abbreviations:** BNT Boston Naming Test Short Form, CDR Clinical Dementia Rating scale, GDS-15 15-item Geriatric Depression Scale, LM-IA Logical Memory Immediate Recall, LM-IIA Logical Memory Delayed Recall, MMSE Mini-Mental State Examination, NPI-Q Neuropsychiatric Inventory-Questionnaire, TMT-A Trail Making Test Part A, TMT-B Trail Making Test Part B, WAIS-R DSC Wechsler Adult Intelligence Scale- Revised Digit Symbol Coding

Hippocampal volume and total brain volume
Hippocampal volume and TBV were included as covariates in the above models to determine if WMH predicted the outcomes independently of these MRI-derived volumetric measures. We performed additional analyses to compare their predictive validity on cognitive change relative to WMH, i.e., we sought to compare effect sizes across the three variables to determine if the effects of WMH are of a similar magnitude. All three variables were transformed into standardized values (i.e., z-scores) based on the baseline scores, and separate models were performed predicting the change in each of the clinical outcomes that demonstrated statistically significant effects with WMH above.
Age at baseline, race, sex, years of education, APOE ε4 carrier status, and the baseline value of the clinical outcome were included as covariates in models. The effect sizes for WMH were of comparable magnitude compared to TBV and hippocampal volume.

Post hoc: depression, cardiovascular disease risk factors, and intracranial volume

Effects for volume of WMH on neuropsychological test performance and diagnostic conversion remained when GDS-15 scores were included as covariates (data not shown). Statistical significance remained unchanged when systolic blood pressure and diagnostic history of hypertension, diabetes, and hypercholesterolemia were entered as additional covariates (data not shown). Statistical significance (including analyses for hippocampal volume) again remained unchanged when ICV was included as a covariate (data not shown).

Discussion

Among participants from the NACC-UDS who were cognitively normal at baseline, higher baseline volume of
Table 3 Post hoc comparisons of the standardized coefficients for WMH, hippocampal volume, and total brain volume in neuropsychological, neuropsychiatric, and functional decline. Standardized beta coefficients are displayed for the interaction effect between the variable and time since baseline. All outcome raw scores were transformed into z-scores based on the performance of the sample at baseline in order to facilitate effect size comparisons between the variables of interest. The interpretation of the standardized beta coefficients is based on SD unit increases between MRI-derived volumetric measure (i.e., log-transformed WMH, hippocampal volume, total brain volume) and the corresponding outcomes age at baseline, sex, race, years of education, and APOE e4 carrier status were included as covariates in each model. The overlap in the absolute values of the confidence intervals demonstrated that no significant differences were observed between the three variables.

| Variable Sum of Boxes | Beta   | 95% CI          | p value |
|-----------------------|--------|-----------------|---------|
| CDR Sum of Boxes      |        |                 |         |
| Log-transformed WMH   | 0.12   | [0.06, 0.19]    | < 0.01  |
| Hippocampal volume    | −0.19  | [−0.29, −0.07]  | < 0.01  |
| Total brain volume    | −0.15  | [−0.23, −0.06]  | < 0.01  |
| Semantic Fluency      |        |                 |         |
| Log-transformed WMH   | −0.03  | [−0.04, −0.02]  | < 0.01  |
| Hippocampal volume    | 0.02   | [0.01, 0.04]    | < 0.01  |
| Total brain volume    | 0.02   | [0.01, 0.04]    | < 0.01  |
| TMT-A                 |        |                 |         |
| Log-transformed WMH   | 0.03   | [0.02, 0.04]    | < 0.01  |
| Hippocampal volume    | −0.03  | [−0.04, −0.01]  | < 0.01  |
| Total brain volume    | −0.02  | [−0.04, −0.01]  | < 0.01  |
| TMT-B                 |        |                 |         |
| Log-transformed WMH   | 0.04   | [0.02, 0.05]    | < 0.01  |
| Hippocampal volume    | −0.03  | [−0.05, −0.01]  | < 0.01  |
| Total brain volume    | −0.03  | [−0.05, −0.01]  | < 0.01  |
| LM-IA                 |        |                 |         |
| Log-transformed WMH   | −0.04  | [−0.07, −0.01]  | 0.01    |
| Hippocampal volume    | 0.03   | [0.01, 0.06]    | 0.01    |
| Total brain volume    | 0.02   | [−0.02, 0.04]   | 0.23    |
| LM-IIA                |        |                 |         |
| Log-transformed WMH   | −0.03  | [−0.06, −0.00]  | 0.02    |
| Hippocampal volume    | 0.04   | [0.01, 0.06]    | 0.01    |
| Total brain volume    | 0.01   | [−0.02, 0.03]   | 0.50    |
| WAIS-R DSC            |        |                 |         |
| Log-transformed WMH   | −0.04  | [−0.06, −0.02]  | < 0.01  |
| Hippocampal volume    | 0.02   | [0.00, 0.03]    | 0.03    |
| Total brain volume    | 0.02   | [0.01, 0.04]    | 0.01    |
| GDS-15                |        |                 |         |
| Log-transformed WMH   | 0.02   | [0.01, 0.04]    | < 0.01  |
| Hippocampal volume    | −0.01  | [−0.03, 0.00]   | 0.08    |
| Total brain volume    | −0.01  | [−0.03, 0.02]   | 0.61    |

WMH predicted an accelerated decline in executive function, attention and psychomotor speed, verbal learning and memory, and semantic fluency. Greater volume of baseline WMH additionally corresponded to accelerated functional decline and increases in self-reported symptoms of depression over time. All effects were independent of baseline age, sex, race, years of education, APOE e4 carrier status, TBV, and hippocampal volume, as well as CVD risk factors. The magnitude of effects for WMH was comparable to TBV and hippocampal volume. Baseline volume of WMH did not predict increased odds for diagnostic conversion. Overall, these findings suggest that WMH are an early and independent correlate of cognitive, neuropsychiatric, and functional decline.

For neuropsychological tests, baseline volume of WMH had the strongest effects for accelerated decline on measures that assess cognitive flexibility (TMT-B), working memory and information processing speed (WAIS-R DSC), and learning and encoding (LM Immediate Recall). LM scores actually improved over time, reflecting the sensitivity of this test to learning effects [76], although rate of improvement was slowest for those in the highest WMH quartile (learning effects are discussed further below). It is also noteworthy that WMH demonstrated an association with Semantic Fluency, but not BNT. This could reflect the greater variability of scores for Semantic Fluency. Alternatively, while both assess semantic memory, semantic fluency tasks have a significant executive function loading [79] that may have driven the effects for WMH. In addition to the effects of WMH on neuropsychological testing, baseline volume of WMH also predicted increases on the CDR Sum of Boxes over time, suggesting possible contribution of WMH to declines in everyday functioning. Similar findings were reported in 1290 individuals from the Northern Manhattan Study (NOMAS) [80]. The association between WMH and worsening self-reported symptoms of depression is similar to previous research from the Framingham Heart Study [77] and consistent with the known association between vascular disease and depression [81, 82].

The effects for WMH on the neuropsychological, neuropsychiatric, and functional measures were independent of, and comparable in magnitude to, TBV and hippocampal volume. Previous findings from Brickman et al. showed that volume of WMH had greater predictive validity for incident dementia relative to hippocampal volume [47]. Among older adults with NC from ADNI, volume of WMH and APOE e4 status were more strongly associated with cortical amyloid status on PET compared to other traditional biomarkers of AD, including FDG-PET and hippocampal volume [21]. WMH on MRI seem to be capturing unique pathophysiological
processes and represents a sensitive (and practical) method for the early detection of cognitive and neuropsychiatric decline, monitoring of disease progression, and the study of white matter pathways in aging and neurodegeneration.

Baseline volume of WMH did not independently predict diagnostic conversion to MCI. In contrast, WMH predicted change for each neuropsychological test score investigated independent of age. The clinical meaningfulness is unclear due to the relatively small effect sizes as can be observed in Fig. 2 that shows the relationship between WMH quartiles and raw neuropsychological test performance. As an example, for Trail Making Test B, individuals in the highest two quartiles (i.e., greatest WMH burden) experienced a mean increase of 2.9 s per year, whereas individuals in the lowest quartile slowed by 0.9 s per year. The relatively small effect sizes are expected given the sample included participants with baseline NC where there are only subtle, if any, cognitive, neuropsychiatric, and functional impairments and changes. Examination of continuous neuropsychological test scores is perhaps optimal for the detection of brain behavior relationships particularly in the absence or early stages of disease.

The current study used FLAIR WMH to provide further insight into the complicated role of CSVD in early cognitive decline. Greater than 50% of dementia cases throughout the world are associated with CSVD [18, 83–86] and 80% of patients diagnosed with AD have cerebrovascular disease pathology at autopsy [31]. CSVD is a broad term that refers to pathologies of the cerebral arteries, arterioles, capillaries, and venules [20]. WMH are widely supported to be markers of CSVD associated with aging and CVD [10–17]. Yet, our sensitivity analyses showed that the effects of WMH remained after controlling for CVD risk factors (i.e., systolic blood pressure, diagnostic history of hypertension, diabetes, and hypercholesterolemia). Although assessments of CVD and related lifestyle behaviors (e.g., exercise, diet) were limited in this study, increasing research suggests that WMH represent white matter pathologies not solely due to CVD and could reflect white matter damage (e.g., axonal loss, demyelination) related to AD, even in the early stages of the disease [23, 87]. The underlying pathologies of WMH may also change throughout the progression of AD [20].

Regardless of etiology, WMH are known to affect the clinical expression of AD [88] and contribute to cognitive heterogeneity in the early stages of disease, including executive dysfunction [23, 89–91]. We propose that CSVD and/or other pathologies of the white matter may contribute to dysexecutive clinical presentations. Previous research has failed to detect an association between WMH and cognitive decline using memory-based measures [92].

The limitations of the NACC-UDS battery preclude the ability to disentangle a distinct executive cognitive profile. Only Logical Memory assessed episodic memory, and word list learning tasks are not part of the NACC-UDS. Other research has also shown that WMH correlates with amnestic MCI and continuous memory tests [93], although the extent to which these effects are frontal versus hippocampal-mediated is uncertain. Nonetheless, approximately 10–40% of patients with underlying AD neuropathologic changes present with an initial behavioral and dysexecutive syndrome as opposed to episodic memory impairment [1, 43–45]. This dysexecutive clinical phenotype of AD has been described elsewhere [1, 45, 94–96] and is associated with genetic risk factors [95] and the presence of co-morbid neurodegenerative disease pathologies (e.g., frontotemporal lobar degeneration [FTLD]) [45]. The dysexecutive phenotypes of clinical AD are associated with a more rapid progression [96, 97] that could be attenuated if its cause is due to modifiable risk factors.

There are several limitations to the present findings. The present study did not include biomarker assessment of underlying AD pathology, including amyloid or p-tau pathology. Only a few NACC ADCs contribute CSF biomarker data and there is no standardized protocol for the collection and biomarker analysis of CSF. The relationships between WMH and CSF [22] and PET [21, 98] biomarkers for AD have been reported previously. For this study, most participants remained cognitively normal, only 52 participants were excluded due to non-AD suspected etiologies (for those who converted), and statistically significant effects remained when these 52 participants were included. WMH might therefore have similar cognitive and neuropsychiatric effects, regardless of the underlying etiology.

Learning effects may have led to an underestimation of the effects of WMH on neuropsychological test performance over time. Yet, learning effects may also have had minimal influence on the estimated effects for several reasons. First, time since baseline (r = 0.97 with number of UDS visits) was included in the statistical models to account for differences in number of exposures to neuropsychological tests. Second, the longitudinal statistical models for neuropsychological test performance included all participants and all study visits. Therefore, if learning effects were present, those with low WMH burden would be expected to demonstrate improved performance over time, whereas participants with high WMH burden would show a smaller than expected learning curve. Such pattern would provide evidence for the detrimental effects of WMH and this was only observed for LM, i.e., scores on LM improved over time, but the rate of improvement was slowest for those with the most WMH burden. The LM test is known for its sensitivity to learning effects [76, 99–101]. Research
in the NACC-UDS has shown that these learning effects become statistically and clinically significant at visit 6 and so on, and the current study had, on average, 5 years of follow-up visits. Aside from LM, other UDS tests have not been shown to have learning effects [66].

There is limited serial quantitated MRI data available from NACC, and it will be essential to leverage the NACC data set in the future to examine changes in WMH and its correspondence to neuropsychological, neuropsychiatric, and functional decline. We examined total WMH volume and evolving research shows there are differential regional effects for WMH in predicting cognitive outcomes [32, 47]. WMH were associated with GDS-15 scores, but not the NPI-Q. This is possibly due to differences in the symptom dimensions assessed and method of data reporting (patient versus informant-reported, respectively) between the two measures. The NPI-Q was also developed as an index of symptoms observed in dementia and may have lacked sensitivity in this sample of cognitively normal participants. Finally, NACC data is derived from convenience samples and participants are not randomly sampled from the general population. The participants and selection of participants are further different across the ADCs that contribute data to NACC, including some centers that might actually exclude participants based on vascular disease (e.g., stroke).

Conclusions
Greater baseline volume of FLAIR MRI WMH was associated with neuropsychological, neuropsychiatric, and functional decline independent of traditional risk factors and MRI biomarkers for AD in this sample of participants with baseline NC from the NACC-UDS. The recent NIA-Alzheimer’s Association research framework emphasizes biomarkers of amyloid, tau, and neurodegeneration for the detection, diagnosis, and study of AD [3]. Integration of CSVD into diagnostic, pathogenic, and treatment models of AD might be indicated [3, 4, 88, 102], but disenfranchising the precise role of CSVD in the clinical and neuro-pathological expression of AD remains warranted.

Abbreviations
AD: Alzheimer’s disease; ADC: Alzheimer’s Disease Center; ADNI: Alzheimer’s Disease Neuroimaging Initiative; BNT: Boston Naming Test; CDR: Clinical Dementia Rating; CSF: Cerebrospinal Fluid; CSVD: Cerebral small vessel disease; CVD: Cardiovascular disease; FDR: False discovery rate; FLAIR: Fluid-attenuated inversion recovery; GDS: Geriatric Depression Scale; GEE: Generalized estimating equations; LM: Logical Memory; MCI: Mild cognitive impairment; Miese: Mini-Mental State Examination; MRI: Magnetic resonance imaging; NACC: National Alzheimer’s Coordinating Center; NC: Normal cognition; NPI-Q: Neuropsychiatric Inventory-Questionnaire; TBV: Total brain volume; TMT: Trail Making Test; UDS: Uniform Data Set; WAIS-R: Wechsler Adult Intelligence Scale; Revised Digit Symbol Coding; WMH: White matter hyperintensities

Acknowledgements
The NACC database is funded by NIA/NIH Grant U01 AG016976. NACC data are contributed by the NIA-funded ADCs. P30 AG013846 (PI Neil Kowall, MD), P50 AG08702 (PI Scott Small, MD), P30 AG025688 (PI Allan Levey, MD, PhD), P50 AG047266 (PI Todd Golde, MD, PhD), P30 AG010133 (PI Andrew Saykin, PsyD), P50 AG001546 (PI Marilyn Albert, PhD), P50 AG005134 (PI Bradley Hyman, MD, PhD), P50 AG016574 (PI Ronald Petersen, MD, PhD), P50 AG005138 (PI Mary Sano, PhD), P30 AG008051 (PI Thomas Winikiewicz, MD), P30 AG013854 (PI M. Marsel Mesulam, MD), P30 AG08017 (PI Jeffrey Kaye, MD), P30 AG010161 (PI David Bennett, MD), P50 AG047366 (PI Victor Henderson, MD, NS), P30 AG010129 (PI Charles DeCarli, MD), P50 AG016573 (PI Frank LaFerla, PhD), P50 AG005131 (PI James Brewer, MD, PhD), P50 AG023501 (PI Bruce Miller, MD), P30 AG035982 (PI Russell Swedo, MD), P30 AG028383 (PI Linda Van Bokk, PhD), P30 AG053760 (PI Henry Paulson, MD, PhD), P30 AG010124 (PI John Trojanowski, MD, PhD), P50 AG005133 (PI Oscar Lopez, MD), P50 AG005142 (PI Helena Chui, MD), P30 AG012300 (PI Roger Rosenberg, MD), P50 AG049638 (PI Suzanne Craft, PhD), P50 AG005136 (PI Thomas Grabowski, MD), P50 AG035314 (PI Sanjay Asthana, MD, FRCP), P50 AG005681 (PI John Morris, MD), P50 AG047270 (PI Stephen Strittmatter, MD, PhD).

Authors’ contributions
CP, CL, NAS, YT, BM, JM, RJK, RAS, and MLA assisted with the conception and design of the study; the acquisition, analysis, and/or interpretation of data; and drafting and revising the manuscript. JNP, EGS, TDS, NWK, and ACM assisted with the interpretation of data and drafting and revising the manuscript. All authors read and approved the final manuscript and have agreed to be personally accountable for their contributions and the integrity and accuracy of the work.

Funding
This work was supported by grants from the NIH (P30AG13846; U01NS093334; K23NS102399; K23AG046377; RF1AG054146). This publication was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through BU-CTSI Grant Number U11TR001430. The content is solely the responsibility of the authors. There is no sponsor.

Availability of data and materials
The data sets generated and/or analyzed during the current study are available through the publicly available National Alzheimer’s Coordinating Center UDS database. The current set includes data from the June 2018 NACC data freeze.

Ethics approval and consent to participate
The NACC-UDS is approved by the University of Washington Institutional Review Board and participants provided informed consent at the ADC where they completed their study visits.

Consent for publication
Not applicable.

Competing interests
RAS is a member of the Mackey-White Committee of the NFL Players Association. He is a paid consultant to Biogen (Cambridge, MA, USA) and Eli Lilly (Indianapolis, IN, USA). He receives royalties for published neuropsychological tests from Psychological Assessment Resources, Inc. (Lutz, FL, USA) and is a member of the Board of Directors of King-Devick Technologies (Chicago, IL, USA). MLA has received honorarium for serving as a Scientific Advisor to Corinno Therapeutics, Inc. There are no other possible conflicts of interest by other co-authors on this manuscript.

Author details
1Boston University Alzheimer’s Disease Center and CTE Center, Boston University School of Medicine, 72 E. Concord Street, Suite 87800, Boston, MA 02118, USA. 2Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA. 3Biostatistics and Epidemiology Data Analytics Center, Boston University School of Public Health, Boston, MA, USA. 4Department of Neurology, Boston University School of Medicine, Boston, MA, USA. 5Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA, USA. 6VA Boston Healthcare System, U.S. Department of Veterans Affairs, Jamaica Plain, USA. 7Department of Anatomy and Neurobiology, Boston University School of Medicine, Boston, MA, USA. 8Center for Biomedical Imaging, Boston University School of Medicine,
1. Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13: 241–9.

2. Dubois B, Hampel H, Feldman HH, et al. Preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria. Alzheimers Dementia. 2016; 12:292–323.

3. Jack CR Jr, Bennett DA, Blennow K, et al. NIH-AA research framework toward a biological definition of Alzheimer’s disease. Alzheimers Dementia. 2018;14:535–62.

4. Jack CR Jr, Bennett DA, Blennow K, et al. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87: 539–47.

5. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dementia. 2011;7:280–92.

6. Johnson KA, Schultz A, Betensky RA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79:110–9.

7. Kang JH, Korecka M, Figurski MJ, et al. The Alzheimer’s Disease Neuroimaging Initiative 2 Biomarker Core: a review of progress and plans. Alzheimers Dementia. 2015;11:772–91.

8. Olsson B, Launer L, Andreasson U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15:567–84.

9. Palmqvist S, Zetterberg H, Mattsson N, et al. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology. 2015;85:1240–9.

10. Brickman AM, Gutzman VA, Gonzalez-Castellon M, et al. Cerebral autoregulation, beta amyloid, and white matter hyperintensities are interrelated. Neurosci Lett. 2015;592:54–8.

11. Dallaire-Theroux C, Callahan BL, Potvin O, Saikali S, Duchesne S. Radiological-pathological correlation in Alzheimer’s disease: systematic review of antemortem magnetic resonance imaging findings. J Alzheimers Dis. 2017;57:575–601.

12. Garde E, Mortensen EL, Krabbe K, Rostrup E, Larsson HB. Relation between age-related decline in intelligence and cerebral white-matter hyperintensities in healthy octogenarians: a longitudinal study. Lancet. 2000; 356:628–34.

13. Holland CM, Smith EE, Cospo I, et al. Spatial distribution of white-matter hyperintensities in Alzheimer disease, cerebral amyloid angiopathy, and healthy aging. Stroke. 2008;39:1127–33.

14. O’Sullivan M, Lythgoe DJ, Pereira AC, et al. Patterns of cerebral blood flow reduction in patients with ischemic leukoaraiosis. Neurology. 2002;59:321–6.

15. Shim YS, Yang DW, Roe CM, et al. Pathological correlates of white matter hyperintensities on magnetic resonance imaging. Dement Geriatr Cogn Disord. 2015;39:92–104.

16. Wolters FJ, Zonneveld IH, Hofman A, et al. Cerebral perfusion and the risk of dementia: a population-based study. Circulation. 2017;136:719–28.

17. de Havenon A, Majersik J, Tischwell DL, McNally JS, Stoddard G, Rost NS. Blood flow, glycemic control, and white matter hyperintensity progression in type 2 diabetes. Neurology. 2019;92(11):e1168–75.

18. Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12:282–38.

19. Traylor M, Tozer DJ, Croll ID, et al. Genetic variation in PLEKHG1 is associated with white matter hyperintensities (n = 11,226). Neurology. 2019;92(7):e749–e57.

20. Shi Y, Wardlaw JM. Update on cerebral small vessel disease: a dynamic whole-brain disease. Stroke Vasc Neurol. 2016;1:83–92.

21. Kandel BM, Avants BB, Gee JC, et al. White matter hyperintensities are more highly associated with preclinical Alzheimer’s disease than imaging and cognitive markers of neurodegeneration. Alzheimers Dementia (Amst). 2016;4: 18–27.
46. Brickman AM, Zahodne LB, Guzman VA, et al. Reconsidering harbingers of dementia: progression of parietal lobe white matter hyperintensities predicts Alzheimer’s disease incidence. Neurobiol Aging. 2015;36:27–32.

47. Brickman AM, Provenzano FA, Muraskin J, et al. Regional white matter hyperintensity volume, not hippocampal atrophy, predicts incident Alzheimer disease in the community. Arch Neurol. 2012;69:1621–7.

48. Tosto G, Zimmerman ME, Hamilton JL, Carmichael OT, Brickman AM. Alzheimer’s Disease Neuroimaging Initiative I. The effect of white matter hyperintensities on neurodegeneration in mild cognitive impairment. Alzheimers Dement. 2015;11:1510–9.

49. van Straaten EC, Harvey D, Scheltens P, et al. Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia. J Neurol. 2008;255:1302–8.

50. Bangen KJ, Preis SR, Delano-Wood L, et al. Baseline white matter hyperintensities and hippocampal volume are associated with conversion from normal cognition to mild cognitive impairment in the Framingham Offspring Study. Alzheimer Dis Assoc Disord. 2018;32:50–6.

51. Nolte-Chamoun G, Moura A, Duchesne S, Bocti C. Alzheimer’s Disease Neuroimaging I. White matter hyperintensities in mild cognitive impairment and lower risk of cognitive decline. J Alzheimers Dis. 2015;46:685–62.

52. Smith EE, Egorova S, Blacker D, et al. Magnetic resonance imaging white matter hyperintensities and brain volume in the prediction of mild cognitive impairment and dementia. Arch Neurol. 2008;65:94–100.

53. Sepe-Monti M, Pantano P, Vancaro N, et al. Vascular risk factors and white matter hyperintensities in patients with amnestic mild cognitive impairment. J Neurosci. 2007;37:419–24.

54. Devine ME, Fonseca JA, Walker Z, Do cerebral white matter lesions influence the rate of progression from mild cognitive impairment to dementia? Int Psychogeriatr. 2013;25:120–7.

55. Schneider JA, Avantakzis L, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol. 2000;46:200–8.

56. Carmichael O, Schwarz C, Drucker D, et al. Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. Arch Neurolog. 2010;67:1370–8.

57. Maillard P, Carmichael O, Fletcher E, Reed B, Munadas D, DeCarli C. Coevolution of white matter hyperintensities and cognition in the elderly. Neurology. 2012;79:442–8.

58. Lockhart SN, Roach AE, Luck SJ, et al. White matter hyperintensities are associated with visual search behavior independent of generalized slowing in aging. Neuropsychologia. 2015;4:93–101.

59. Beekly DL, Ramos EM, van Belle G, et al. The National Alzheimer’s Coordinating Center’s uniform data set. Alzheimer Dis Assoc Disord. 2009;23:91–10.

60. Morris JC, Weintraub S, Chui HC, et al. The uniform data set (UDS): clinical and cognitive variables and descriptive data from Alzheimer disease centers. Alzheimer Dis Assoc Disord. 2006;20:210–6.

61. Weintraub S, Salmon D, Mercaldo N, et al. The Alzheimer’s disease Centers’ uniform data set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord. 2009;23:91–101.

62. Besser L, Kukull W, Knopman DS, et al. Version 3 of the National Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:270–9.

63. McKhann GM, Kropman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9.

64. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRSA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology. 1984;34:939–44.

65. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:568–72.

66. Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993;43:2412–4.

67. Halekoh U, Højsgaard S, Yan J. The R package geepack for generalized estimating equations. J Stat Softw. 2006;15:1–11.

68. R Core Team. R: A language and environment for statistical computing; 2014 [Available from: http://www.R-project.org/]. Accessed May 2019.

69. Gavett BE, Gumani AS, Saumrun JL, et al. Practice effects on story memory and list learning tests in the neuropsychological assessment of older adults. PLoS One. 2016;11:e0164492.

70. Yu WQ, Himmal JJ, Wolf PA, DeCarli DC, Beiser A, Au R. Effects of white matter integrity and brain volumes on late life depression in the Framingham Heart Study Int J Geriatr Psychiatry. 2013;7:214–21.

71. Rock PL, Roiser JP, Riedel WJ, Blackwell AD. Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med. 2014;44:2029–40.

72. Shao Z, Janse E, Visscher K, Meyer AS. What do verbal fluency tasks measure? Predictors of verbal fluency performance in older adults. Front Psychol. 2014;5:772.

73. Dharmoo MS, Cheung YK, Moon Y, et al. Cerebral white matter disease and functional decline in older adults from the northern Manhattan study: a longitudinal cohort study. PLoS Med. 2018;15:e1002529.

74. Matt BT, Yochim B, MacNeill SE, Lichtenberg PA. Risk factors for geriatric depression: the importance of executive functioning within the vascular depression hypothesis. J Gerontol A Biol Sci Med Sci. 2004;59:1290–4.

75. Taylor WD, Abenstein HJ, Alexopoulos GS. The vascular depression hypothesis: mechanisms linking vascular disease with depression. Mol Psychiatry. 2013;18:963–74.

76. Hachinski V, World SO. Stroke and potentially preventable dementia: updated world stroke day proclamation. Stroke. 2015;46:3039–40.

77. Iadecola C. The pathobiology of vascular dementia. Neuron. 2013;80:944–66.

78. Marques TJ, Korfoshez WL, Babcock D, et al. Recommendations of the Alzheimer’s disease-related dementias conference. Neurology. 2014;83:1381–60.

79. Snyder HM, Corriveau RA, Craft S, et al. Vascular contributions to cognitive impairment and dementia: progression of parietal lobe white matter hyperintensities in patients with amnestic mild cognitive impairment. JAMA Neurol. 2013;70:132–3.

80. Delano-Wood L, Bondi MW, Sacco J, et al. Heterogeneity in mild cognitive impairment: differences in neuropsychological profile and associated white matter lesion pathology. J Int Neuropsychol Soc. 2016;22:390–6.

81. Mast BT, Yochim B, MacNeill SE, Lichtenberg PA. Risk factors for geriatric depression: the importance of executive functioning within the vascular depression hypothesis. J Gerontol A Biol Sci Med Sci. 2004;59:1290–4.

82. Rabin JS, Schultz AP, Hedden T, et al. Interactive associations of vascular risk factors, depression, and beta-amyloid burden with cognitive decline in clinically normal elderly individuals: findings from the Harvard Aging Brain Study. JAMA Neurol. 2018;75:1124–31.
93. Luchsinger JA, Brickman AM, Reitz C, et al. Subclinical cerebrovascular disease in mild cognitive impairment. Neurology. 2009;73:450–6.
94. Woodward M, Brodaty H, Boundy K, et al. Does executive impairment define a frontal variant of Alzheimer's disease? Int Psychogeriatr. 2010;22:1280–90.
95. Mez J, Cosentino S, Brickman AM, Huey ED, Manly JJ, Mayeux R. Dysexecutive versus amnestic Alzheimer disease subgroups: analysis of demographic, genetic, and vascular factors. Alzheimer Dis Assoc Disord. 2013;27:218–25.
96. Mez J, Cosentino S, Brickman AM, Huey ED, Manly JJ, Mayeux R. Faster cognitive and functional decline in dysexecutive versus amnestic Alzheimer's subgroups: a longitudinal analysis of the National Alzheimer's Coordinating Center (NACC) database. PLoS One. 2013;8:e65246.
97. Dickerson BC, Wolk DA, Alzheimer's Disease Neuroimaging I. Dysexecutive versus amnestic phenotypes of very mild Alzheimer’s disease are associated with distinct clinical, genetic and cortical thinning characteristics. J Neurol Neurosurg Psychiatry. 2011;82:45–51.
98. Kim HJ, Park S, Cho H, et al. Assessment of extent and role of tau in subcortical vascular cognitive impairment using 18F-AV1451 positron emission tomography imaging. JAMA Neurol. 2018;75:999–1007.
99. Benedict RH, Zgaljardic DJ. Practice effects during repeated administrations of memory tests with and without alternate forms. J Clin Exp Neuropsychol. 1998;20:339–52.
100. Dodge HH, Wang CN, Chang CC, Ganguli M. Terminal decline and practice effects in older adults without dementia: the MoVIES project. Neurology. 2011;77:722–30.
101. Theisen ME, Rapport LJ, Axelrod BN, Brines DB. Effects of practice in repeated administrations of the Wechsler memory scale revised in normal adults. Assessment. 1998;5:85–92.
102. Sweeney MD, Montagne A, Sagare AP, et al. Vascular dysfunction-the disregarded partner of Alzheimer’s disease. Alzheimers Dement. 2019;15:158–67.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.